Sort Through Meds for Managing Hemophilia
December 2018
New meds Jivi (JIH-vee) and Rebinyn (reh-bee-NYNE) will raise questions about managing bleeding in hemophilia patients.
Jivi (recombinant PEGylated factor VIII) will be for hemophilia A. It will compete with other long-acting (Adynovate, Eloctate, etc) and short-acting (Kogenate FS, Recombinate, etc) factor VIII products.
Rebinyn (recombinant glycoPEGylated factor IX) is for the less common hemophilia B. It's an alternative to long-acting (Alprolix, Idelvion, etc) or short-acting (BeneFix, Ixinity, etc) factor IX products.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote